![Cancers | Free Full-Text | Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity Cancers | Free Full-Text | Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity](https://www.mdpi.com/cancers/cancers-13-02492/article_deploy/html/images/cancers-13-02492-g001.png)
Cancers | Free Full-Text | Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity
![Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long‐term outcomes for breast cancer patients - Bossuyt - 2020 - The Breast Journal - Wiley Online Library Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long‐term outcomes for breast cancer patients - Bossuyt - 2020 - The Breast Journal - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/63e4345d-e75b-4600-90ef-3e6ba3e320da/tbj13864-fig-0004-m.jpg)
Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long‐term outcomes for breast cancer patients - Bossuyt - 2020 - The Breast Journal - Wiley Online Library
![Automated and Manual Quantification of Tumour Cellularity in Digital Slides for Tumour Burden Assessment | Scientific Reports Automated and Manual Quantification of Tumour Cellularity in Digital Slides for Tumour Burden Assessment | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-019-50568-4/MediaObjects/41598_2019_50568_Fig1_HTML.png)
Automated and Manual Quantification of Tumour Cellularity in Digital Slides for Tumour Burden Assessment | Scientific Reports
![Good practice: The experiences with the utilization of residual cancer burden—A single institution study - Sejben - Thoracic Cancer - Wiley Online Library Good practice: The experiences with the utilization of residual cancer burden—A single institution study - Sejben - Thoracic Cancer - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/56a455f6-dc53-41ae-9731-deb005c0d70f/tca.v14.7.cover.jpg)
Good practice: The experiences with the utilization of residual cancer burden—A single institution study - Sejben - Thoracic Cancer - Wiley Online Library
![Breast Cancer Molecular Profiles Predict Tumor Response of Neoadjuvant Doxorubicin and Paclitaxel, the I-SPY TRIAL (CALGB /150012, ACRIN 6657) L. - ppt download Breast Cancer Molecular Profiles Predict Tumor Response of Neoadjuvant Doxorubicin and Paclitaxel, the I-SPY TRIAL (CALGB /150012, ACRIN 6657) L. - ppt download](https://images.slideplayer.com/24/7095365/slides/slide_6.jpg)
Breast Cancer Molecular Profiles Predict Tumor Response of Neoadjuvant Doxorubicin and Paclitaxel, the I-SPY TRIAL (CALGB /150012, ACRIN 6657) L. - ppt download
![Parameters for residual cancer burden evaluation (A): Bidimensional... | Download Scientific Diagram Parameters for residual cancer burden evaluation (A): Bidimensional... | Download Scientific Diagram](https://www.researchgate.net/publication/342685228/figure/fig1/AS:974646706978817@1609385291822/Parameters-for-residual-cancer-burden-evaluation-A-Bidimensional-diameter-of-residual.png)
Parameters for residual cancer burden evaluation (A): Bidimensional... | Download Scientific Diagram
![Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy - ScienceDirect Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419313481-gr1.jpg)
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy - ScienceDirect
![A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer - The Breast A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer - The Breast](https://www.thebreastonline.com/cms/asset/b4c9d307-60a2-407a-b21d-bf17e5c213f5/gr1.jpg)
A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer - The Breast
![December 10-14, 2013 An Update on Breast Cancer CCO Independent Conference Coverage of the 2013 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer. - ppt download December 10-14, 2013 An Update on Breast Cancer CCO Independent Conference Coverage of the 2013 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer. - ppt download](https://images.slideplayer.com/47/11712761/slides/slide_68.jpg)
December 10-14, 2013 An Update on Breast Cancer CCO Independent Conference Coverage of the 2013 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer. - ppt download
![Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy | Modern Pathology Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy | Modern Pathology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fmodpathol.2015.53/MediaObjects/41379_2015_Article_BFmodpathol201553_Fig1_HTML.jpg)
Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy | Modern Pathology
Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy | PLOS ONE
![Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration - ScienceDirect Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419344886-gr1.jpg)
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration - ScienceDirect
![Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy | SpringerLink Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1245%2Fs10434-022-12300-x/MediaObjects/10434_2022_12300_Fig1_HTML.png)
Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy | SpringerLink
![Stefania Landolfi on Twitter: "Residual Cancer Burden evaluation in post-NAST #Breastpath #USCAP2018 #insitupathologists https://t.co/4GSxTI47S5" / Twitter Stefania Landolfi on Twitter: "Residual Cancer Burden evaluation in post-NAST #Breastpath #USCAP2018 #insitupathologists https://t.co/4GSxTI47S5" / Twitter](https://pbs.twimg.com/media/DYlT9WBVoAA6vFS.jpg)